Amtagvi
Total Payments
$6.5M
Transactions
1,418
Doctors
409
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.5M | 1,418 | 409 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.4M | 816 | 98.2% |
| Honoraria | $39,995 | 12 | 0.6% |
| Consulting Fee | $33,845 | 16 | 0.5% |
| Food and Beverage | $26,679 | 522 | 0.4% |
| Travel and Lodging | $14,142 | 52 | 0.2% |
Payments by Type
Research
$6.4M
816 transactions
General
$114,661
602 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 101623 | Iovance Biotherapeutics, Inc. | $2.2M | 0 |
| 81990 | Iovance Biotherapeutics, Inc. | $1.2M | 0 |
| 117145 | Iovance Biotherapeutics, Inc. | $827,238 | 0 |
| NCT03108495 | Iovance Biotherapeutics, Inc. | $786,417 | 0 |
| IIT-2022-LDTIL | Iovance Biotherapeutics, Inc. | $324,622 | 0 |
| NCT05361174 | Iovance Biotherapeutics, Inc. | $322,918 | 0 |
| NCT02360579 | Iovance Biotherapeutics, Inc. | $181,731 | 0 |
| IOV-EAP-401 | Iovance Biotherapeutics, Inc. | $164,400 | 0 |
| 131462 | Iovance Biotherapeutics, Inc. | $141,705 | 0 |
| 123745 | Iovance Biotherapeutics, Inc. | $98,417 | 0 |
| 22-109 | Iovance Biotherapeutics, Inc. | $73,015 | 0 |
| Endometrial Preclinical Research: OU202308LH-IOVANCE | Iovance Biotherapeutics, Inc. | $56,170 | 0 |
| IOV-EAP-402 | Iovance Biotherapeutics, Inc. | $20,000 | 0 |
| MCC-19837 | Iovance Biotherapeutics, Inc. | $20,000 | 0 |
Top Doctors Receiving Payments for Amtagvi — Page 17
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Chicago, IL | $5.67 | 1 |
| , D.O | Hematology & Oncology | Chicago, IL | $5.67 | 1 |
| , MD | Hematology & Oncology | Chicago, IL | $5.67 | 1 |
| , NP | Adult Health | Chicago, IL | $5.66 | 1 |
| , MD | Hematology & Oncology | Chicago, IL | $5.66 | 1 |
| , MD | Hematology & Oncology | Chicago, IL | $5.66 | 1 |
| Natalie Hansen | Physician Assistant | New York, NY | $4.51 | 1 |
| , RPA-C | Physician Assistant | New York, NY | $4.51 | 1 |
| , PA-C | Physician Assistant | New York, NY | $4.51 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $2.11 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 409
- Transactions 1,418
About Amtagvi
Amtagvi is a drug associated with $6.5M in payments to 409 healthcare providers, recorded across 1,418 transactions in the CMS Open Payments database. The primary manufacturer is Iovance Biotherapeutics, Inc..
Payment data is available from 2024 to 2024. In 2024, $6.5M was paid across 1,418 transactions to 409 doctors.
The most common payment nature for Amtagvi is "Unspecified" ($6.4M, 98.2% of total).
Amtagvi is associated with 14 research studies, including "101623" ($2.2M).